Meeting
2019 Genitourinary Cancers Symposium
Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.
Authors
Vincenza Conteduca
Weill Cornell Medicine, New York, NY
Vincenza Conteduca , Clara Oromendia , Panagiotis J. Vlachostergios , Amy Hackett , Charlene Thomas , Aidan Case , Jyothi Manohar , Kenneth Eng , Andrea Sboner , Karla V. Ballman , Olivier Elemento , David M. Nanus , Himisha Beltran , Scott T. Tagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 272)
DOI
10.1200/JCO.2019.37.7_suppl.272
Abstract #
272
Poster Bd #
M7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2023 ASCO Annual Meeting
Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.
First Author: Anis Hamid
Poster
2023 ASCO Genitourinary Cancers Symposium
Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers.
First Author: Jones T. Nauseef
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR).
First Author: Kamal Kant Kant Sahu